Simple Summary The field of liquid biopsy is rapidly evolving. Techniques that improve
accuracy are constantly being developed, and clinicians increasingly use liquid biopsy as a …

Liquid biopsy has been introduced as a new diagnostic concept predicated on the analysis
of circulating tumour cells (CTCs) or circulating tumour-derived factors, in particular, cell-free …

Detection of minimal residual disease in patients with cancer, who are in complete remission
with no cancer cells detectable, has the potential to improve recurrence-free survival through …

Liquid biopsy has the potential to provide information about cancers without invasive biopsy,
using circulating biomarkers. These include proteins, RNA and DNA. They can be used in …

Circulating tumor DNA (ctDNA) has emerged as a promising biomarker of minimal residual
disease (MRD) in solid tumors. There is increasing evidence to suggest that the detection of …

Over the last decade, liquid biopsy has gained much attention as a powerful tool in
personalized medicine, since it enables monitoring cancer evolution and follow-up of cancer …

New sensitive assays are currently available for the detection of circulating tumor DNA
(ctDNA) and circulating tumor cells (CTC). However, there remains a need for …

Curative therapies for cancer are often successful when it is early detected and treated.
Cancer screening aims at detecting cancer at early stages, before symptoms appear, and …

Simple Summary Minimal residual disease (MRD) represents a status of the disease which
is assumed to still be present in the body until it is clinically observed by radiology. At this …

Historically, studies of disseminated tumour cells in bone marrow and circulating tumour
cells in peripheral blood have provided crucial insights into cancer biology and the …